0001567619-22-011721.txt : 20220525
0001567619-22-011721.hdr.sgml : 20220525
20220525190515
ACCESSION NUMBER: 0001567619-22-011721
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220523
FILED AS OF DATE: 20220525
DATE AS OF CHANGE: 20220525
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MILLIGAN JOHN F
CENTRAL INDEX KEY: 0001191589
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39782
FILM NUMBER: 22964531
MAIL ADDRESS:
STREET 1: C/O GILEAD SCIENCES, INC.
STREET 2: 333 LAKESIDE DRIVE
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: 4D Molecular Therapeutics, Inc.
CENTRAL INDEX KEY: 0001650648
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473506994
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5858 HORTON STREET #455
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: 5105052680
MAIL ADDRESS:
STREET 1: 5858 HORTON STREET #455
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
FORMER COMPANY:
FORMER CONFORMED NAME: 4D Molecular Therapeutics Inc.
DATE OF NAME CHANGE: 20200506
FORMER COMPANY:
FORMER CONFORMED NAME: 4D Molecular Therapeutics Inc
DATE OF NAME CHANGE: 20150811
4
1
doc1.xml
FORM 4
X0306
4
2022-05-23
0
0001650648
4D Molecular Therapeutics, Inc.
FDMT
0001191589
MILLIGAN JOHN F
C/O 4D MOLECULAR THERAPEUTICS INC.
5858 HORTON STREET #455
EMERYVILLE
CA
94608
1
0
0
0
Stock Option (Right to Buy)
7.77
2022-05-23
4
A
0
33750
0
A
2032-05-22
Common Stock
33750
33750
D
Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2023 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2025. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).
/s/ August J. Moretti, Attorney-in-Fact for John F. Milligan
2022-05-25